Potency assays and biomarkers for cell-based advanced therapy medicinal products

Potency assays and biomarkers for cell-based advanced therapy medicinal products

Advanced Therapy Medicinal Products (ATMPs) based on somatic cells expanded in vitro, with or without genetic modification, is a rapidly growing area of drug development, even more so following the marketing approval of several such products. ATMPs are produced according to Good Manufacturing Practi...

Full description

Bibliographic Details
Main Authors:	Chiara Capelli, Carolina Cuofano, Chiara Pavoni, Simona Frigerio, Daniela Lisini, Sara Nava, Michele Quaroni, Valentina Colombo, Francesco Galli, Svetlana Bezukladova, Paola Panina-Bordignon, Giuseppe Gaipa, Patrizia Comoli, Giulio Cossu, Gianvito Martino, Andrea Biondi, Martino Introna, Josée Golay
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-06-01
Series:	Frontiers in Immunology
Subjects:	advanced therapy medicinal product (ATMP) potency CAR (chimeric antigen receptor) T cell therapy stem cell tissue regeneration
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2023.1186224/full

Similar Items

Potency testing of cell and gene therapy products
by: Paula Salmikangas, et al.
Published: (2023-05-01)

Endogenous neural stem cells characterization using omics approaches: Current knowledge in health and disease
by: Valentina Murtaj, et al.
Published: (2023-04-01)

Neurogenesis and Viral Infection
by: Amadi Ogonda Ihunwo, et al.
Published: (2022-02-01)

Heparin Precursors with Reduced Anticoagulant Properties Retain Antiviral and Protective Effects That Potentiate the Efficacy of Sofosbuvir against Zika Virus Infection in Human Neural Progenitor Cells
by: Isabel Pagani, et al.
Published: (2023-09-01)

Biomaterials enhancing performance of cell and nucleic-acid therapies: An opportunity in the brain
by: Christopher Lally, et al.
Published: (2022-03-01)

Complete intra-laboratory validation of a LAL assay for bacterial endotoxin determination in EBV-specific cytotoxic T lymphocytes
by: Salvatore Pasqua, et al.
Published: (2021-09-01)

Barriers to Treg therapy in Europe: From production to regulation
by: Conor Hennessy, et al.
Published: (2023-01-01)

Basics of advanced therapy medicinal product development in academic pharma and the role of a GMP simulation unit
by: I. Johanna, et al.
Published: (2023-12-01)

Automated, Miniaturized and Integrated Quality Control-on-Chip (QC-on-a-Chip) for Advanced Cell Therapy Applications
by: David eWartmann, et al.
Published: (2015-09-01)

Advanced Therapy Medicinal Products for the Eye: Definitions and Regulatory Framework
by: Marina López-Paniagua, et al.
Published: (2021-03-01)

Analysis of the measurements used as potency tests for the 31 US FDA-approved cell therapy products
by: Carl G. Simon, et al.
Published: (2025-03-01)

Uses and Challenges of Antiviral Polyclonal and Monoclonal Antibody Therapies
by: Evi B. Struble, et al.
Published: (2023-05-01)

The phenotypic convergence between microglia and peripheral macrophages during development and neuroinflammation paves the way for new therapeutic perspectives
by: Francesca Grassivaro, et al.
Published: (2021-01-01)

Towards novel reimbursement models for expensive advanced therapy medicinal products (ATMPs)
by: Dario Picecchi, et al.
Published: (2020-12-01)

Adaptation through Collaboration: Developing Novel Platforms to Advance the Delivery of Advanced Therapies to Patients
by: Magdalini Papadaki
Published: (2017-05-01)

MSC Manufacturing for Academic Clinical Trials: From a Clinical-Grade to a Full GMP-Compliant Process
by: Chantal Lechanteur, et al.
Published: (2021-05-01)

Advanced Therapy medicinal products for autologous chondrocytes and comparison of regulatory systems in target countries
by: Jiwon Kim, et al.
Published: (2022-06-01)

Two Decades of Global Progress in Authorized Advanced Therapy Medicinal Products: An Emerging Revolution in Therapeutic Strategies
by: Roya Ramezankhani, et al.
Published: (2020-12-01)

Education for the translation of Advanced Therapy Medicinal Products
by: Davide Adamo, et al.
Published: (2023-04-01)

Microbiological Aspects of Pharmaceutical Manufacturing of Adipose-Derived Stem Cell-Based Medicinal Products
by: Ilona Szabłowska-Gadomska, et al.
Published: (2023-02-01)

How to Avoid a No-Deal ER Exit
by: Tiziana Anelli, et al.
Published: (2019-09-01)

Editorial: Translating NK cell scientific research to clinical product manufacturing
by: Evelyn Ullrich, et al.
Published: (2023-08-01)

Advanced Therapies for Human Immunodeficiency Virus
by: Daniel Josef Lindegger
Published: (2024-07-01)

Editorial: Clinical Translation and Commercialisation of Advanced Therapy Medicinal Products
by: Ivan Martin, et al.
Published: (2020-12-01)

Enhanced Anti-Babesia Efficacy of Buparvaquone and Imidocarb When Combined with ELQ-316 In Vitro Culture of <i>Babesia bigemina</i>
by: Natalia M. Cardillo, et al.
Published: (2025-02-01)

Comprehensive high-resolution genomic profiling and cytogenetics of human chondrocyte cultures by GTG-banding, locus-specific FISH, SKY and SNP array
by: M Wallenborn, et al.
Published: (2018-04-01)

Optimization of the Production Process of Clinical-Grade Human Salivary Gland Organoid-Derived Cell Therapy for the Treatment of Radiation-Induced Xerostomia in Head and Neck Cancer
by: Jacoba van Zanten, et al.
Published: (2024-03-01)

Retrospective Analysis of Autologous Chondrocyte-Based Cytotherapy Production for Clinical Use: GMP Process-Based Manufacturing Optimization in a Swiss University Hospital
by: Virginie Philippe, et al.
Published: (2022-03-01)

Bioengineered tissue and cell therapy products are efficiently cryopreserved with pathogen-inactivated human platelet lysate-based solutions
by: María Martín-López, et al.
Published: (2023-04-01)

Mitigating Deficiencies in Evidence during Regulatory Assessments of Advanced Therapies: A Comparative Study with Other Biologicals
by: Magdi Elsallab, et al.
Published: (2020-09-01)

The issue of heterogeneity of MSC-based advanced therapy medicinal products–a review
by: Ana Bajc Česnik, et al.
Published: (2024-07-01)

GMP-Grade Manufacturing and Quality Control of a Non-Virally Engineered Advanced Therapy Medicinal Product for Personalized Treatment of Age-Related Macular Degeneration
by: Martina Kropp, et al.
Published: (2022-11-01)

RESTORE Survey on the Public Perception of Advanced Therapies and ATMPs in Europe—Why the European Union Should Invest More!
by: Gady Goldsobel, et al.
Published: (2021-10-01)

Characteristics of Medical Products Comprising Human Cells, Genes, or Tissues Developed in Japan and the European Union Compared via Public Assessment Reports
by: Ryosuke Kurauchi, et al.
Published: (2020-12-01)

Price and reimbursement of advanced therapeutic medicinal products in Europe: are assessment and appraisal diverging from expert recommendations?
by: Virginia Ronco, et al.
Published: (2021-12-01)

ATMP Environmental Exposure Assessment in European Healthcare Settings: A Systematic Review of the Literature
by: Margaux Damerval, et al.
Published: (2021-12-01)

Therapeutic Plasticity of Neural Stem Cells
by: Linda Ottoboni, et al.
Published: (2020-03-01)

Toxicology and Biodistribution: The Clinical Value of Animal Biodistribution Studies
by: Beatriz Silva Lima, et al.
Published: (2018-03-01)

Regulatory-Compliant Validation of a Highly Sensitive qPCR for Biodistribution Assessment of Hemophilia A Patient Cells
by: Patrick Bittorf, et al.
Published: (2020-09-01)

The Relevance of Advanced Therapy Medicinal Products in the Field of Transplantation and the Need for Academic Research Access: Overcoming Bottlenecks and Claiming a New Time
by: Lorenzo Piemonti, et al.
Published: (2023-09-01)